BioInvent International (STO:BINV)24% confirmed ORR (including complete response) in heavily pretreated patients (n=25) with advanced ovarian cancer who received BI-1808 and KEYTRUDA - multiplying by ...

BioInvent International (STO:BINV)24% confirmed ORR (including complete response) in heavily pretreated patients (n=25) with advanced ovarian cancer who received BI-1808 and KEYTRUDA - multiplying by ...

WhiteFiber, Inc. ("WhiteFiber" or the "Company"), a leading provider of AI infrastructure and high-performance computing solutions, today announced that it has entered into a five-year agreement to ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending ...

Fulgent Genetics, Inc. ("Fulgent" or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that its ...

RBC Capital Markets Global Healthcare Conference 2026 May 19, 2026 9:00 AM EDTCompany ParticipantsAndrew Peters - Senior ...

Key Points Interested in Exelixis, Inc.? Here are five stocks we like better. Exelixis is leaning on CABO growth in renal ...

Could the new “7-minute cancer shot” mark a major shift in modern cancer care, making treatment faster, less exhausting and ...

MSD's Keytruda is poised to end a 20-year drought in new advances in NHS treatment for early-stage head and neck cancer, after being recommended by reimbursement authority NICE. In final draft ...

Preview ASCO 2026 late-breaking cancer trials—from TNBC ADC survival gains to lung, liver, prostate and myeloma readouts ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that together with Kite, a Gilead company, it will present more than 25 abstracts, including six oral presentations, at the 2026 ASCO Annual ...